Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
COPENHAGEN, March 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks.
The data is seen as crucial for the future potential for its experimental next-generation obesity drug, after results published in December from another trial with the drug in people without diabetes showed lower-than-expected weight loss.
The new data released on Monday from the phase III trial called REDEFINE 2 was based on about 1,200 people with type 2 diabetes and a body mass index (BMI) of or above 27 after 68 weeks.
The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial, Novo Nordisk said in a statement.
After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose, it added.
If all people adhered to treatment with CagriSema, patients overall achieved weight loss of 15.7% after 68 weeks, compared to 31.1% with placebo.
CagriSema is a weekly injection that combines semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone GLP-1, and a separate molecule called cagrilintide that mimics the pancreatic hormone amylin, into a weekly injection.
The two hormones combined suppress hunger and help control patients' blood glucose.
here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
a day ago
- Reuters
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
June 13 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on Friday. The 12-week result was published in an abstract ahead of the American Diabetes Association conference in Chicago, the brokerage said. Cantor analyst Prakhar Agrawal said the data on eloralintide looked strong in terms of weight loss and safety, adding that expectations for the drug had been low. The drug belongs to a class of medicines that mimic the pancreatic hormone amylin, which is co-secreted with insulin. Amylin slows digestion and suppresses hunger. Mid-stage trials are ongoing, both as a standalone treatment and in combination with Lilly's blockbuster GLP-1 drug, tirzepatide, sold as Zepbound. The first wave of obesity drugs focused mainly on the gut hormone GLP-1, but drugmakers are now looking for medicines that target other hormones or help preserve muscle mass during fat-loss for their next generation of drugs. We think the data today is a sign that the real successor to tirzepatide is the tirzepatide-eloralintide combo, said Jefferies analyst Akash Tewari. In March, Roche (ROG.S), opens new tab acquired the rights to Zealand Pharma's long-acting amylin analogue, petrelintide, in a collaboration valued at up to $5.3 billion. Similarly, Novo Nordisk ( opens new tab is banking on a dual mode of action involving amylin for its next generation of drugs, with experimental compounds called amycretin and CagriSema, while AstraZeneca (AZN.L), opens new tab has an amylin-based obesity drug in early trials. Lilly's eloralintide weight-loss data is tracking better than Roche and Zealand's petrelintide, said Agrawal, adding the data is meaningfully better than Novo's monotherapy. Data at 12 weeks is also competitive compared to other drug classes such as GLP-1, Agrawal also said. Eli Lilly did not immediately respond to a Reuters request for comment.
Reuters
2 days ago
- Reuters
Russia says it tests new laser defences against drones
MOSCOW, June 13 (Reuters) - Russia said on Friday it had conducted large-scale tests of new laser-based systems to defend against drones. A government statement described the new technology as "promising" and said it had been tested against various types of drone in different weather conditions. It said the anti-drone lasers would become part of a "universal air defence system" that President Vladimir Putin said this week Russia needed to build. "The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons. Conducting tests allows us to move on to serial production and upscaling," the statement said. An accompanying video showed charred debris from a destroyed drone. Both sides have deployed drones on a huge scale in the Russia-Ukraine war, using them to spot and hit targets not only on the battlefield but way beyond the front lines. Ukrainian drones have frequently struck sites deep inside Russia such as oil depots, refineries and airfields, highlighting the need for Moscow to boost its defences. Earlier this month, Ukrainian drones smuggled close to air bases in trucks inflicted serious damage to Russia's long-range bomber fleet.
Reuters
3 days ago
- Reuters
US health chief says Sen. Cassidy promised pick on vaccine panel
WASHINGTON, June 12 (Reuters) - U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said he told U.S. Senator Bill Cassidy that he would allow Cassidy to pick a candidate for a key panel of vaccine advisers. Cassidy, a Republican, serves as chairman the U.S. Senate Health, Education, Labor, and Pensions Committee. "What I told Senator Cassidy is that I would allow him to put one of his candidates on, which we're going to do," Kennedy said on Thursday during an interview on Fox News' "The Story with Martha MacCallum," referring to the vaccine advisory panel. Kennedy on Wednesday named eight members to serve on the U.S. Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices, which advises the agency on who should get the shots after they are approved by the U.S. Food and Drug Administration, after gutting the panel last week.
